Home
|
Contact
|
Pharmacovigilance
|
Medical Information
|
ITA
ENG
Welcome to
Chiesi group
Enter at least 3 characters
About us
History
Mission and Values
Governance
Benefit Corporation and B Corp
Annual and Sustainability Report
Chiesi in the world
Main areas
Research and Development
Clinical Trial Transparency and Data Sharing
Chiesi Clinical Studies
Manufacturing plants
Partnering
Why Chiesi as a partner
Therapeutic Focus
Who we are
Where we are
Events
Open Innovation - The Impulse
Digital Health
Working at Chiesi
Sustainability
Our approach
Ethics and Transparency
Patients at the Center
Environment
Global Value Chain
Chiesi people
Communities
Media area
News
Press Release
Contact
Home
>
Press release
Elgan Pharma and Chiesi Group Announce First Participating Infants Dosed in...
Nazareth, Israel and Parma, Italy, June 05, 2025 – Elgan Pharma Ltd. and Chiesi Farmaceutici S.p.A today announced the dosing of the first...
Purpose First: Chiesi Publishes 2024 Sustainability Report
Chiesi Group delivers on transformational strategy with FY2024 double-digit...
ARCHIVE PRESS RELEASE
Chiesi Global Rare Diseases Announces FDA Approval of Lamzede® (velmanase alfa-tycv) for Alpha-Mannosidosis
22 Febbraio 2023
Chiesi appoints Giuseppe Accogli as new Group CEO
27 Gennaio 2023
Important recognitions for Chiesi Group from the Carbon Disclosure Project (CDP) and Cerved Rating Agency
17 Gennaio 2023
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
08 Gennaio 2023
Chiesi Group communicates that it is not involved in the events concerning the Holostem company
05 Dicembre 2022
Chiesi Group endorses the Manifesto Against Gender-Based Violence
28 Novembre 2022
Chiesi Group’s new Biotech Center of Excellence brings the future of medicine to Parma
21 Novembre 2022
Chiesi Group and Aptar partner to bring to market Disease Management Platform for Patients with Asthma and COPD
18 Ottobre 2022
Chiesi is recertified as a B Corp and sets new tougher objectives for action by 2025
22 Settembre 2022
Chiesi Group brings together experts to discuss care for respiratory patients and presents a new treatment option for COPD at ERS Congress
05 Settembre 2022
<<
1
2
3
4
5
6
7
8
9
CHIESI ON THE WEB
Australia
Chiesi Australia
Austria
Chiesi Pharmaceuticals GmbH
Belgium
Chiesi SA/NV
Brazil
Chiesi Farmacêutica Ltda
Bulgaria
Chiesi Bulgaria EOOD
Canada
Chiesi Canada Corp
China
Chiesi Pharmaceutical (Shanghai) Co., Ltd
Czech Republic
Chiesi CZ s.r.o.
Denmark
Chiesi Pharma AB
Finland
Chiesi Pharma AB
France
Chiesi SAS
Germany
Chiesi GmbH
Greece
Chiesi Hellas Α.Ε.Β.Ε.
Hungary
Chiesi Hungary Kft.
Italy
CHIESI Italia S.p.A.
Japan
Chiesi Pharma Japan K.K.
Mexico
CHIESI MÉXICO
Norway
Chiesi Pharma AB
Pakistan
CHIESI PAKISTAN
Poland
Chiesi Poland
Romania
Chiesi România S.r.l.
Russian Federetion
Chiesi Pharmaceuticals LLC
Slovak Republic
Chiesi Slovakia s.r.o
Slovenia
Chiesi Slovenija, d.o.o
Spain
CHIESI ESPAÑA S.A.U
Sweden
Chiesi Pharma AB
The Netherlands
Chiesi Pharmaceuticals B.V.
Turkey
Chiesi İlaç Ticaret A.Ş
United Kingdom
Chiesi Limited
United States
Chiesi Usa, Inc.